Chikhani C G, Kumar K
Department of Accident and Emergency Medicine, Milton Keynes General Hospital, England.
Arch Emerg Med. 1988 Mar;5(1):4-11. doi: 10.1136/emj.5.1.4.
The various guidelines for the administration of tetanus toxoid and antitetanus immunoglobulin are not only complicated, but also have never been supported by any scientific experimental studies. This study has measured the antibody levels in a random sample of 157 patients presenting to an accident and emergency department. Levels were measured before and after boosting doses. The results show that, in the sample analyzed, even those patients who had their last 'booster' over 10 years ago, had a satisfactory immunoglobulin level. In fact, no patient in the study had a level below the 'protective level'. Bearing in mind the small number of patients in the study, it could be argued that the level of immunity against tetanus in the United Kingdom is likely to be higher than assumed. If this is proven to be correct, then the length of time between booster injections of toxoid can be extended and the use of Human Antitetanus Immunoglobulin can be further restricted.
破伤风类毒素和破伤风抗免疫球蛋白的各种管理指南不仅复杂,而且从未得到任何科学实验研究的支持。本研究对157名到急诊部门就诊的患者随机样本的抗体水平进行了测量。在加强剂量前后分别进行了测量。结果显示,在所分析的样本中,即使是那些最后一次“加强”超过10年前的患者,其免疫球蛋白水平也令人满意。事实上,研究中没有患者的水平低于“保护水平”。考虑到研究中的患者数量较少,可以认为英国的破伤风免疫水平可能高于预期。如果这被证明是正确的,那么类毒素加强注射之间的时间间隔可以延长,人破伤风免疫球蛋白的使用可以进一步受限。